Maze Therapeutics

news & press

latest press coverage

latest media coverage

Forbes: Third Rock And ARCH-Backed Genetics Startup Launches With Nearly $200 Million

Forbes — A startup aimed at identifying genetic modifiers (genes that impact how other ones are expressed) to develop new drugs launched Thursday with $191 million in funding from investors Third Rock Ventures and ARCH Venture Partners, among others. Maze…

Xconomy: With $191M Haul, Maze Therapeutics Takes Aim at Genetic Diseases

Xconomy San Francisco — People who share the same disease-causing genetic mutation can have a wide range of severity in their disease. Some don’t get sick at all. Environment can play a role, but with ever-more genetic data available, scientists…

MIT Technology Review: The secret to a new drug could be hiding in your genes

MIT Technology Review — Sickle-cell disease is caused by a one-letter spelling mistake in the hemoglobin gene. But not everyone who inherits the error suffers the worst effects of the blood disease. By 2008, scientists had figured out why. It’s…

want to get a hold of a representative?

Media Inquires

Katie Engleman